Can-Fite Biopharma Says Its Phase 3 Study For Namodenoson For Advanced Liver Cancer Is 31 Recruiting Medical Centers. Namodenoson Has Orphan Drug Status From FDA And European Medicines Agency, And FDA Fast Track Status
Can-Fite Biopharma Says Its Phase 3 Study For Namodenoson For Advanced Liver Cancer Is 31 Recruiting Medical Centers. Namodenoson Has Orphan Drug Status From FDA And European Medicines Agency, And FDA Fast Track Status
can-fite biopharma稱其第3期肝癌進階治療藥物Namodenoson的研究共有31個醫療中心正在進行招募。Namodenoson已獲得美國FDA和歐洲藥品管理局的孤兒藥物地位，以及FDA Fast Track狀態。
A compassionate use program has also been ongoing in Israel and Romania.
以色列和羅馬尼亞也一直在進行一項同情使用計劃。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。